Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues

Igor P. Oscorbin, Alexandra S. Shadrina, Vadim V. Kozlov, Vladimir E. Voitsitsky, Maxim L. Filipenko

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


EGFR tyrosine-kinase inhibitors (TKIs) are used as targeted therapeutics for the treatment of advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations. EGFR C797S is common causes of acquired resistance to third-generation TKIs. There is wide-spread opinion that resistance-conferring mutation present even in a small proportion of cancer cells before the start of therapy could potentially predict poor response to a targeted drug. In our study, we tested whether C797S can be found in previously untreated NSCLCs. We analyzed DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue sections of 470 lung adenocarcinoma patients, including 235 samples with activating EGFR mutations. Screening was performed using highly sensitive droplet digital PCR assay. No tumor samples with baseline C797S were identified. C797S does not occur in TKI-naïve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.

Original languageEnglish
Pages (from-to)1229-1234
Number of pages6
JournalPathology and Oncology Research
Issue number2
Publication statusPublished - 1 Apr 2020


  • C797S
  • Droplet digital PCR
  • EGFR
  • Non-small cell lung cancer
  • Osimertinib


Dive into the research topics of 'Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues'. Together they form a unique fingerprint.

Cite this